Rhythm Pharmaceuticals Current Ratio Growth & History (RYTM)
Rhythm Pharmaceuticals's current ratio was 4.41 for fiscal 2025.
View full Rhythm Pharmaceuticals company overviewRhythm Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 4.41 | 1.17 | +36.05% |
| 2024 | 2024-12-31 | 3.24 | −2.34 | −41.99% |
| 2023 | 2023-12-31 | 5.58 | −3.31 | −37.24% |
| 2022 | 2022-12-31 | 8.90 | 1.80 | +25.31% |
| 2021 | 2021-12-31 | 7.10 | −2.99 | −29.66% |
| 2020 | 2020-12-31 | 10.10 | −2.29 | −18.48% |
| 2019 | 2019-12-31 | 12.38 | −6.66 | −34.97% |
| 2018 | 2018-12-31 | 19.05 | −3.37 | −15.05% |
| 2017 | 2017-12-31 | 22.42 | 20.06 | +849.22% |
| 2016 | 2016-12-31 | 2.36 | — | — |
Rhythm Pharmaceuticals quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.45 | 0.67 | +23.88% |
| Q1 2026 | 2026-03-31 | 4.17 | 0.87 | +26.20% |
| Q4 2025 | 2025-12-31 | 4.41 | 1.17 | +36.05% |
| Q3 2025 | 2025-09-30 | 4.75 | 1.26 | +36.10% |
| Q2 2025 | 2025-06-30 | 2.79 | −3.74 | −57.34% |
| Q1 2025 | 2025-03-31 | 3.30 | −1.05 | −24.13% |
| Q4 2024 | 2024-12-31 | 3.24 | −2.34 | −41.99% |
| Q3 2024 | 2024-09-30 | 3.49 | −3.08 | −46.89% |
| Q2 2024 | 2024-06-30 | 6.53 | 0.37 | +6.06% |
| Q1 2024 | 2024-03-31 | 4.35 | −2.55 | −36.96% |
| Q4 2023 | 2023-12-31 | 5.58 | −3.31 | −37.24% |
| Q3 2023 | 2023-09-30 | 6.57 | −4.37 | −39.95% |
| Q2 2023 | 2023-06-30 | 6.16 | 0.56 | +10.07% |
| Q1 2023 | 2023-03-31 | 6.91 | 1.54 | +28.80% |
| Q4 2022 | 2022-12-31 | 8.90 | 1.80 | +25.31% |
| Q3 2022 | 2022-09-30 | 10.93 | −3.37 | −23.56% |
| Q2 2022 | 2022-06-30 | 5.59 | −16.08 | −74.19% |
| Q1 2022 | 2022-03-31 | 5.36 | −19.10 | −78.08% |
| Q4 2021 | 2021-12-31 | 7.10 | −2.99 | −29.66% |
| Q3 2021 | 2021-09-30 | 14.30 | 1.06 | +7.98% |
| Q2 2021 | 2021-06-30 | 21.68 | 5.72 | +35.85% |
| Q1 2021 | 2021-03-31 | 24.46 | 9.32 | +61.59% |
| Q4 2020 | 2020-12-31 | 10.10 | −2.29 | −18.48% |
| Q3 2020 | 2020-09-30 | 13.25 | 6.47 | +95.39% |
| Q2 2020 | 2020-06-30 | 15.96 | 8.16 | +104.57% |
| Q1 2020 | 2020-03-31 | 15.14 | −3.18 | −17.35% |
| Q4 2019 | 2019-12-31 | 12.38 | −6.66 | −34.97% |
| Q3 2019 | 2019-09-30 | 6.78 | −28.66 | −80.87% |
| Q2 2019 | 2019-06-30 | 7.80 | −32.32 | −80.56% |
| Q1 2019 | 2019-03-31 | 18.32 | −6.49 | −26.18% |
| Q4 2018 | 2018-12-31 | 19.05 | −3.37 | −15.05% |
| Q3 2018 | 2018-09-30 | 35.44 | 29.57 | +504.01% |
| Q2 2018 | 2018-06-30 | 40.12 | — | — |
| Q1 2018 | 2018-03-31 | 24.81 | — | — |
| Q4 2017 | 2017-12-31 | 22.42 | 20.06 | +849.22% |
| Q3 2017 | 2017-09-30 | 5.87 | — | — |
| Q4 2016 | 2016-12-31 | 2.36 | — | — |
Rhythm Pharmaceuticals current ratio trends
Over the last five fiscal years, Rhythm Pharmaceuticals's current ratio decreased from 10.10 to 4.41, a change of −5.69. The latest reported quarter, Q2 2026, shows 3.45.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rhythm Pharmaceuticals source filings ↗